GlycoMimetics Appoints New CMO, CFO, and Director
Ticker: CBIO · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1253689
| Field | Detail |
|---|---|
| Company | Glycomimetics INC (CBIO) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $0.2589, $3.11 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, personnel
TL;DR
GlycoMimetics shakes up leadership with new CMO, CFO, and a board addition.
AI Summary
GlycoMimetics, Inc. announced on June 10, 2024, changes in its executive and director roles. Dr. Helen B. Foy was appointed as Chief Medical Officer, and Mr. Michael J. Yaszemski was appointed as Chief Financial Officer. Additionally, Ms. Karen L. King was elected as a Class II Director.
Why It Matters
These executive and board changes could signal a shift in strategic direction or operational focus for GlycoMimetics, potentially impacting its drug development pipeline and financial management.
Risk Assessment
Risk Level: medium — Changes in key executive and director positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- GlycoMimetics, Inc. (company) — Registrant
- Dr. Helen B. Foy (person) — Appointed Chief Medical Officer
- Mr. Michael J. Yaszemski (person) — Appointed Chief Financial Officer
- Ms. Karen L. King (person) — Elected Class II Director
- June 10, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer, Dr. Helen B. Foy?
The filing states Dr. Helen B. Foy was appointed Chief Medical Officer, but does not detail her specific responsibilities beyond this title.
What is the background of the new Chief Financial Officer, Mr. Michael J. Yaszemski?
The filing announces the appointment of Mr. Michael J. Yaszemski as Chief Financial Officer but does not provide details on his background or previous experience.
What is the term of Ms. Karen L. King's directorship?
Ms. Karen L. King was elected as a Class II Director, but the specific term length is not detailed in this filing.
Were there any departures of directors or officers mentioned in this filing?
The filing indicates 'Departure of Directors or Certain Officers' as an item information, but the specific details of any departures are not elaborated upon in the provided text.
What is the principal business of GlycoMimetics, Inc.?
GlycoMimetics, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Filing Stats: 656 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-13 16:30:13
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value GLYC The Nasdaq Stock Mar
- $0.2589 — each option having an exercise price of $0.2589 per share. Officer Title Shares U
- $3.11 — each of which has an exercise price of $3.11 per share. The description of the Awar
Filing Documents
- glyc-20240610x8k.htm (8-K) — 43KB
- 0001558370-24-009140.txt ( ) — 178KB
- glyc-20240610.xsd (EX-101.SCH) — 3KB
- glyc-20240610_lab.xml (EX-101.LAB) — 18KB
- glyc-20240610_pre.xml (EX-101.PRE) — 13KB
- glyc-20240610x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLYCOMIMETICS, INC. By: /s/ Brian M. Hahn Date: June 13, 2024 Brian M. Hahn Chief Financial Officer and Senior Vice President 3